Progress of chronic myeloid leukemia / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 133-136, 2022.
Article
in Chinese
| WPRIM
| ID: wpr-929747
ABSTRACT
In the tyrosine kinase inhibitor (TKI) therapy era, patients with chronic myeloid leukemia (CML) have embarked on the trend of "chronic disease management". With the advent of 4 generations TKI drugs, there remain unmet needs for optimal CML treatment, such as treatment-free remission and disease recurrence after discontinuation. This article reviews the research progress of CML at the 63rd American Society of Hematology annual meeting.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of Leukemia & Lymphoma
Year:
2022
Type:
Article
Similar
MEDLINE
...
LILACS
LIS